Pharma Industry

President Trump says it’s necessary to impose extra costs on goods from Canada, Mexico and China. What does that mean for the health care sector? Potentially, a lot.

Executive order says HHS will ‘rapidly enforce’ price disclosures by hospitals, health insurers.

UCLA research highlights the widespread use of non-evidence-based treatments during the COVID-19 pandemic, raising concerns about the role of misinformation and health care spending.

Both sides support revising laws for PBM market, but Democrats and Republicans disagree on potential Medicaid changes.

Prevention beats treatment for everyone — patients, payers and investors.

Bargaining for widely used prescription drugs may save money for Medicare, but AAR wants seniors to see better prices at the pharmacy counter.

A discussion about the Medicare Drug Price Negotiation Program with Adina Lasser, director of public policy and government affairs with the Alliance for Aging Research.

A study of the medical economics of ultraprocessed foods, diabetes and pharmaceutical revenues.

A discussion about the Medicare Drug Price Negotiation Program with Adina Lasser, director of public policy and government affairs with the Alliance for Aging Research.

A discussion about the Medicare Drug Price Negotiation Program with Adina Lasser, director of public policy and government affairs with the Alliance for Aging Research.

What new treatments mean for practices and patients.

A discussion about the Medicare Drug Price Negotiation Program with Adina Lasser, director of public policy and government affairs with the Alliance for Aging Research.

A discussion about the Medicare Drug Price Negotiation Program with Adina Lasser, director of public policy and government affairs with the Alliance for Aging Research.

A discussion about the Medicare Drug Price Negotiation Program with Adina Lasser, director of public policy and government affairs with the Alliance for Aging Research.

A discussion about the Medicare Drug Price Negotiation Program with Adina Lasser, director of public policy and government affairs with the Alliance for Aging Research.

A discussion about the Medicare Drug Price Negotiation Program with Adina Lasser, director of public policy and government affairs with the Alliance for Aging Research.

An expert on antimicrobial resistance discusses how it involves patients in local doctors’ offices and around the world.

Study examined Amazon’s RxPass to see how it affected medication adherence and cost

An infectious disease expert describes the state of AMR – and how to fight it.

An infectious disease expert describes the state of AMR – and how to fight it.

An infectious disease expert describes the state of AMR – and how to fight it.

An infectious disease expert describes the state of AMR – and how to fight it.

An infectious disease expert describes the state of AMR – and how to fight it.

An infectious disease expert describes the state of AMR – and how to fight it.

An infectious disease expert describes the state of AMR – and how to fight it.